nomifensine has been researched along with Dizzyness in 1 studies
Nomifensine: An isoquinoline derivative that prevents dopamine reuptake into synaptosomes. The maleate was formerly used in the treatment of depression. It was withdrawn worldwide in 1986 due to the risk of acute hemolytic anemia with intravascular hemolysis resulting from its use. In some cases, renal failure also developed. (From Martindale, The Extra Pharmacopoeia, 30th ed, p266)
nomifensine : An N-methylated tetrahydroisoquinoline carrying phenyl and amino substituents at positions C-4 and C-8, respectively.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Side effect information was collected at each visit." | 2.65 | An overview of side effects and long-term experience with nomifensine from United States clinical trials. ( Hardiman, S; Nash, RJ; Yakabow, AL, 1984) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yakabow, AL | 1 |
| Hardiman, S | 1 |
| Nash, RJ | 1 |
1 trial available for nomifensine and Dizzyness
| Article | Year |
|---|---|
An overview of side effects and long-term experience with nomifensine from United States clinical trials.
Topics: Adult; Akathisia, Drug-Induced; Clinical Trials as Topic; Depressive Disorder; Dizziness; Headache; | 1984 |